{
  "openalex_id": "W2119700304",
  "doi": "https://doi.org/10.1128/mcb.00112-09",
  "title": "The Small Molecule GMX1778 Is a Potent Inhibitor of NAD<sup>+</sup> Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors",
  "abstract": "GMX1777 is a prodrug of the small molecule GMX1778, currently in phase I clinical trials for the treatment of cancer. We describe findings indicating that GMX1778 is a potent and specific inhibitor of the NAD(+) biosynthesis enzyme nicotinamide phosphoribosyltransferase (NAMPT). Cancer cells have a very high rate of NAD(+) turnover, which makes NAD(+) modulation an attractive target for anticancer therapy. Selective inhibition by GMX1778 of NAMPT blocks the production of NAD(+) and results in tumor cell death. Furthermore, GMX1778 is phosphoribosylated by NAMPT, which increases its cellular retention. The cytotoxicity of GMX1778 can be bypassed with exogenous nicotinic acid (NA), which permits NAD(+) repletion via NA phosphoribosyltransferase 1 (NAPRT1). The cytotoxicity of GMX1778 in cells with NAPRT1 deficiency, however, cannot be rescued by NA. Analyses of NAPRT1 mRNA and protein levels in cell lines and primary tumor tissue indicate that high frequencies of glioblastomas, neuroblastomas, and sarcomas are deficient in NAPRT1 and not susceptible to rescue with NA. As a result, the therapeutic index of GMX1777 can be widended in the treatment animals bearing NAPRT1-deficient tumors by coadministration with NA. This provides the rationale for a novel therapeutic approach for the use of GMX1777 in the treatment of human cancers.",
  "authors": [
    {
      "display_name": "Mark H. Watson",
      "id": "A5111531725",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": true,
      "raw_author_name": "Mark Watson"
    },
    {
      "display_name": "Anne Roulston",
      "id": "A5056470194",
      "orcid": "https://orcid.org/0000-0003-4814-8242",
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Anne Roulston"
    },
    {
      "display_name": "Laurent Bélec",
      "id": "A5102810085",
      "orcid": "https://orcid.org/0000-0002-3950-2513",
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Laurent Bélec"
    },
    {
      "display_name": "Xavier Billot",
      "id": "A5066246443",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Xavier Billot"
    },
    {
      "display_name": "Richard Marcellus",
      "id": "A5114045958",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Richard Marcellus"
    },
    {
      "display_name": "Dominique Bédard",
      "id": "A5110310760",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Dominique Bédard"
    },
    {
      "display_name": "Cynthia Bernier",
      "id": "A5010527031",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Cynthia Bernier"
    },
    {
      "display_name": "Stéphane Branchaud",
      "id": "A5070086293",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Stéphane Branchaud"
    },
    {
      "display_name": "Helen Chan",
      "id": "A5030140827",
      "orcid": "https://orcid.org/0000-0002-7917-4411",
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Helen Chan"
    },
    {
      "display_name": "Kenza Daïri",
      "id": "A5030160091",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Kenza Dairi"
    },
    {
      "display_name": "Karine Gilbert",
      "id": "A5020294966",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Karine Gilbert"
    },
    {
      "display_name": "Daniel Goulet",
      "id": "A5105935584",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Daniel Goulet"
    },
    {
      "display_name": "Michel‐Olivier Gratton",
      "id": "A5045661706",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Michel-Olivier Gratton"
    },
    {
      "display_name": "Henady Isakau",
      "id": "A5053013346",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Henady Isakau"
    },
    {
      "display_name": "Anne Jang",
      "id": "A5060823915",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Anne Jang"
    },
    {
      "display_name": "Abdelkrim Khadir",
      "id": "A5101503602",
      "orcid": "https://orcid.org/0000-0002-2502-5306",
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Abdelkrim Khadir"
    },
    {
      "display_name": "Elizabeth M. Koch",
      "id": "A5051670000",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Elizabeth Koch"
    },
    {
      "display_name": "Manon Lavoie",
      "id": "A5006096896",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Manon Lavoie"
    },
    {
      "display_name": "Michael Lawless",
      "id": "A5090077330",
      "orcid": "https://orcid.org/0000-0001-6874-9307",
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Michael Lawless"
    },
    {
      "display_name": "Mai Nguyen",
      "id": "A5101450213",
      "orcid": "https://orcid.org/0000-0002-9723-6321",
      "institutions": [
        {
          "id": "I5023651",
          "display_name": "McGill University",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Mai Nguyen"
    },
    {
      "display_name": "Denis Paquette",
      "id": "A5085138351",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Denis Paquette"
    },
    {
      "display_name": "Émilie Turcotte",
      "id": "A5065884358",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Émilie Turcotte"
    },
    {
      "display_name": "Alvin Berger",
      "id": "A5110237977",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210123764",
          "display_name": "Metabolon (United States)",
          "country_code": "US",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Alvin Berger"
    },
    {
      "display_name": "Matthew Mitchell",
      "id": "A5008874428",
      "orcid": "https://orcid.org/0000-0002-2681-4091",
      "institutions": [
        {
          "id": "I4210123764",
          "display_name": "Metabolon (United States)",
          "country_code": "US",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Matthew Mitchell"
    },
    {
      "display_name": "Gordon C. Shore",
      "id": "A5113572579",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        },
        {
          "id": "I5023651",
          "display_name": "McGill University",
          "country_code": "CA",
          "type": "funder"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Gordon C. Shore"
    },
    {
      "display_name": "Pierre Beauparlant",
      "id": "A5034442828",
      "orcid": null,
      "institutions": [
        {
          "id": "I4210127345",
          "display_name": "Xenon Pharmaceuticals (Canada)",
          "country_code": "CA",
          "type": "company"
        }
      ],
      "is_corresponding": false,
      "raw_author_name": "Pierre Beauparlant"
    }
  ],
  "publication_year": 2009,
  "publication_date": "2009-08-25",
  "type": "article",
  "cited_by_count": 211,
  "is_retracted": false,
  "is_paratext": false,
  "language": "en",
  "source": {
    "id": "S81455967",
    "display_name": "Molecular and Cellular Biology",
    "issn_l": "0270-7306",
    "issn": [
      "0270-7306",
      "1067-8824",
      "1098-5549"
    ],
    "type": "journal",
    "host_organization": "https://openalex.org/P4310320547"
  },
  "volume": "29",
  "issue": "21",
  "first_page": "5872",
  "last_page": "5888",
  "open_access": {
    "is_oa": true,
    "oa_status": "green",
    "oa_url": "https://europepmc.org/articles/pmc2772749?pdf=render",
    "any_repository_has_fulltext": true
  },
  "concepts": [
    {
      "id": "C2780391879",
      "display_name": "Nicotinamide phosphoribosyltransferase",
      "level": 4,
      "score": 0.9781849
    },
    {
      "id": "C75520062",
      "display_name": "NAD+ kinase",
      "level": 3,
      "score": 0.9356434
    },
    {
      "id": "C86803240",
      "display_name": "Biology",
      "level": 0,
      "score": 0.730423
    },
    {
      "id": "C2777991568",
      "display_name": "Phosphoribosyltransferase",
      "level": 5,
      "score": 0.6060686
    },
    {
      "id": "C2779728014",
      "display_name": "Nicotinamide",
      "level": 3,
      "score": 0.6029928
    },
    {
      "id": "C502942594",
      "display_name": "Cancer research",
      "level": 1,
      "score": 0.5650653
    },
    {
      "id": "C109316439",
      "display_name": "Cytotoxicity",
      "level": 3,
      "score": 0.5513569
    },
    {
      "id": "C181199279",
      "display_name": "Enzyme",
      "level": 2,
      "score": 0.5025554
    },
    {
      "id": "C2776901170",
      "display_name": "Nicotinamide adenine dinucleotide",
      "level": 4,
      "score": 0.4646399
    },
    {
      "id": "C108215921",
      "display_name": "Prodrug",
      "level": 2,
      "score": 0.45103228
    },
    {
      "id": "C55493867",
      "display_name": "Biochemistry",
      "level": 1,
      "score": 0.44477507
    },
    {
      "id": "C96232424",
      "display_name": "Cancer cell",
      "level": 3,
      "score": 0.4269237
    },
    {
      "id": "C121608353",
      "display_name": "Cancer",
      "level": 2,
      "score": 0.40796855
    },
    {
      "id": "C202751555",
      "display_name": "In vitro",
      "level": 2,
      "score": 0.26876166
    },
    {
      "id": "C78179603",
      "display_name": "Hypoxanthine-guanine phosphoribosyltransferase",
      "level": 4,
      "score": 0.080631614
    },
    {
      "id": "C104317684",
      "display_name": "Gene",
      "level": 2,
      "score": 0.07518083
    },
    {
      "id": "C54355233",
      "display_name": "Genetics",
      "level": 1,
      "score": 0.06197974
    },
    {
      "id": "C143065580",
      "display_name": "Mutant",
      "level": 3,
      "score": 0.0
    }
  ],
  "topics": [
    {
      "id": "T13415",
      "display_name": "Calcium signaling and nucleotide metabolism",
      "score": 0.9993
    },
    {
      "id": "T11051",
      "display_name": "Sirtuins and Resveratrol in Medicine",
      "score": 0.999
    },
    {
      "id": "T11914",
      "display_name": "PARP inhibition in cancer therapy",
      "score": 0.9988
    }
  ],
  "created_date": null,
  "updated_date": null,
  "indexed_in": [],
  "landing_page_url": "https://doi.org/10.1128/mcb.00112-09",
  "pdf_url": null,
  "retrieved_date": "2025-07-30T16:01:44.901026",
  "source_database": "OpenAlex"
}